Nitrocine (Glyceryl Trinitrate)

Glyceryl trinitrate is a nitric‑oxide donor. After it enters the bloodstream, it is converted to nitric oxide, which activates soluble guanylate cyclase in vascular smooth‑muscle cells. This raises cyclic GMP levels, causing smooth‑muscle relaxation, vasodilation of veins and arteries, reduced cardiac preload and afterload, and consequently a lower myocardial oxygen demand.

The appropriate dose of Nitrocine is determined by the prescribing clinician based on the patient’s clinical condition, response, and tolerance. Dosing regimens are individualized and may involve continuous infusion or intermittent bolus administration under close hemodynamic monitoring.

Safety data for glyceryl trinitrate during pregnancy and lactation are limited. The drug should only be used when the potential maternal benefit justifies any possible risk to the fetus or infant, and the decision must be made by the treating physician after careful assessment.

To order Nitrocine, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the sales team provides pricing, availability, shipping details (including cold‑chain handling if required) and assists with any necessary import documentation.

Nitrocine (glyceryl trinitrate) is a short‑acting nitrate that provides rapid onset of vasodilation when given intravenously, making it suitable for emergency situations. Longer‑acting oral nitrates such as isosorbide dinitrate have a slower onset and are used for chronic angina prophylaxis. The intravenous route of Nitrocine allows precise titration, whereas oral agents rely on fixed dosing schedules.

Nitrocine must be stored at 2‑8 °C in a refrigerator, protected from light. The solution should not be frozen or shaken, and any unused portion should be discarded according to local regulations after the recommended shelf‑life once removed from controlled storage.

Nitrocine is administered by intravenous injection or infusion. The healthcare professional prepares the solution under aseptic conditions, connects it to an IV line, and adjusts the infusion rate or administers bolus doses while continuously monitoring blood pressure, heart rate and clinical response.

The most serious risks include severe hypotension that can lead to syncope or organ hypoperfusion, methemoglobinemia which impairs oxygen delivery, and rare allergic reactions that may progress to anaphylaxis. Prompt recognition and immediate management of these events are essential.

Nitrocine should be avoided in patients with known hypersensitivity to glyceryl trinitrate or other organic nitrates, those taking phosphodiesterase‑5 inhibitors, and individuals with severe aortic stenosis or uncontrolled hypotension. Caution is also advised in patients with recent head injury, elevated intracranial pressure, or significant anemia.